Prospective case–control study of nonfatal cancer preceding the diagnosis of parkinson’s disease (original) (raw)

Abstract

Objective

Prior studies suggest a decreased frequency of cancer in patients with Parkinson’s disease (PD). We conducted a nested case–control study to estimate the association between the diagnosis of PD and a history of preceding cancer.

Methods

Our case–control study was nested within a prospective cohort of 22,071 US male physicians. During 22 years of follow-up, 487 incident cases of PD were identified and matched by age to 487 controls. We then evaluated a history of cancer prior to the index date that was confirmed by medical record review.

Results

The frequency of any cancer was less in cases (13.1%) than in controls (14.8%). There was an inverse relationship between overall cancer (odds ratio [OR] = 0.83; 95% CI, 0.57–1.21), smoking-related (OR = 0.74; 95% CI, 0.35–1.57), and non-smoking-related cancer (OR = 0.88; 95% CI, 0.59–1.32) and the subsequent development of PD. Smoking significantly modified the relationship between PD and smoking-related cancer (p interaction = 0.002). PD cases who smoked had an OR of 0.32 (95% CI, 0.11–0.89) for smoking-related cancer. In contrast, PD cases who never smoked had an OR of 6.85 (95% CI, 0.83–56.39).

Conclusions

Our data suggest that the frequency of cancer preceding the diagnosis of PD is decreased. Smoking status prior to PD or cancer diagnosis significantly modified the association between smoking-related cancer and PD.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52:395–398
    PubMed CAS Google Scholar
  2. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310:1500–1501
    PubMed CAS Google Scholar
  3. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) A typical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205
    Article PubMed CAS Google Scholar
  4. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247:429–434
    Article PubMed CAS Google Scholar
  5. Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17:505–509
    Article PubMed CAS Google Scholar
  6. Pritchard PB 3rd, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 23:215–222
    PubMed Google Scholar
  7. Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case–control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37:226–232
    PubMed CAS Google Scholar
  8. West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease and cancer. Trends Neurosci 28:348–352
    Article PubMed CAS Google Scholar
  9. Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA (2002) Nonfatal cancer preceding Parkinson’s disease: a case–control study. Epidemiology 13:157–164
    Article PubMed Google Scholar
  10. Olsen JH, Friis S, Frederiksen K (2006) Malignant Melanoma and other types of cancer preceding Parkinson Disease. Epidemiology 17:582–587
    Article PubMed Google Scholar
  11. D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, Savettieri G (2004) Tumor diagnosis preceding Parkinson’s disease: a case–control study. Mov Disord 19:807–811
    Article PubMed Google Scholar
  12. Final report on the aspirin component of the ongoing Physicians’ Health Study (1989) Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 321:129–135
    Google Scholar
  13. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145–1149
    Article PubMed CAS Google Scholar
  14. Christen WG, Gaziano JM, Hennekens CH (2000) Design of Physicians’ Health Study II – a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 10:125–134
    Article PubMed CAS Google Scholar
  15. The health consequences of smoking: cancer: a report of the surgeon general (1982) In: Shopland DR (ed) Centers for disease control and prevention (CDC), Office on Smoking and Health, pp 5–6
  16. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284
    Article PubMed Google Scholar
  17. Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96
    Article PubMed Google Scholar
  18. Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2006) Survival of Parkinson’s disease patients in a large prospective cohort of male health professionals. Mov Disord 21:1002–1007
    Article PubMed Google Scholar
  19. Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC et al (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 339:1375–1377
    Article PubMed CAS Google Scholar
  20. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238
    Article PubMed CAS Google Scholar
  21. Lim KL, Dawson VL, Dawson TM (2003) The cast of molecular characters in Parkinson’s disease: felons, conspirators, and suspects. Ann N Y Acad Sci 991:80–92
    Article PubMed CAS Google Scholar
  22. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179:38–46
    Article PubMed CAS Google Scholar
  23. McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 56:149–162
    Article PubMed CAS Google Scholar
  24. Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8:313–317
    PubMed CAS Google Scholar
  25. Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Maraganore DM, Rocca WA (2005) Education and occupations preceding Parkinson disease: a population-based case–control study. Neurology 65:1575–1583
    Article PubMed CAS Google Scholar
  26. Chen H, Zhang SM, Schwarzschild MA, Hernan MA, Ascherio A (2005) Physical activity and the risk of Parkinson disease. Neurology 64:664–669
    PubMed CAS Google Scholar
  27. Camargo CA Jr, Hennekens CH, Gaziano JM, Glynn RJ, Manson JE, Stampfer MJ (1997) Prospective study of moderate alcohol consumption and mortality in US male physicians. Arch Intern Med 157:79–85
    Article PubMed Google Scholar
  28. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM (2004) Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63:1240–1244
    PubMed Google Scholar
  29. Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52:1214–1220
    PubMed CAS Google Scholar
  30. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022
    Article Google Scholar

Download references

Acknowledgments

We are grateful to the staff of the Physician’s Health Study and to the 22,071 dedicated physicians who have made this project possible.

Author information

Authors and Affiliations

  1. Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA, 02120-1613, USA
    Jane A. Driver, Tobias Kurth, Julie E. Buring, J. Michael Gaziano & Giancarlo Logroscino
  2. Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
    Tobias Kurth, Julie E. Buring & J. Michael Gaziano
  3. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Tobias Kurth, Julie E. Buring & Giancarlo Logroscino
  4. Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA, USA
    Julie E. Buring
  5. Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA, USA
    J. Michael Gaziano

Authors

  1. Jane A. Driver
  2. Tobias Kurth
  3. Julie E. Buring
  4. J. Michael Gaziano
  5. Giancarlo Logroscino

Corresponding author

Correspondence toTobias Kurth.

Additional information

This study was supported by grants CA 34944 and CA 40360 from the National Cancer Institute, and grants HL-26490 and HL-34595 from the National Heart, Lung and Blood Institute Bethesda MD.

Rights and permissions

About this article

Cite this article

Driver, J.A., Kurth, T., Buring, J.E. et al. Prospective case–control study of nonfatal cancer preceding the diagnosis of parkinson’s disease.Cancer Causes Control 18, 705–711 (2007). https://doi.org/10.1007/s10552-007-9005-9

Download citation

Keywords